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Associations of Proinflammatory Cytokines With the
Risk of Recurrent Stroke
Paul Welsh, BSc; Gordon D.O. Lowe, DSc; John Chalmers, MD, PhD; Duncan J. Campbell, MD, PhD;
Ann Rumley, PhD; Bruce C. Neal, PhD; Stephen W. MacMahon, PhD; Mark Woodward, PhD
Background and Purpose—There are few reports on proinflammatory cytokines and risk of primary or recurrent stroke.
We studied the association of interleukin (IL)-6, IL-18, and tumor necrosis factor- (TNF-) with recurrent stroke in
a nested case-control study derived from the Perindopril Protection Against Recurrent Stroke Study (PROGRESS).
Methods—We performed a nested case-control study of 591 strokes (472 ischemic, 83 hemorrhagic, 36 unknown subtype)
occurring during a randomized, placebo-controlled multicenter trial of perindopril-based therapy in 6105 patients with
a history of stroke or transient ischemic attack. Controls were matched for age, treatment group, sex, region, and most
recent qualifying event at entry to the parent trial.
Results—IL-6 and TNF-, but not IL-18, were associated with risk of recurrent ischemic stroke independently of
conventional risk markers. Adjusted odds ratios comparing the highest to lowest third of their distributions were 1.33
(95% CI, 1.00 to 1.78) for IL-6 and 1.46 (1.02 to 2.10) for TNF-. No inflammatory marker was associated with
hemorrhagic stroke risk. In multivariable models, IL-6 and TNF- fully explained observed associations of C-reactive
protein and fibrinogen with risk of ischemic stroke, but TNF- retained borderline significance after full adjustment.
Conclusions—Inflammatory markers associated with the acute-phase response (IL-6, TNF-, C-reactive protein, and
fibrinogen, but not IL-18) are associated with risk of recurrent stroke. These markers are dependent on each other in
multivariable models, and once all were included, only TNF- retained a borderline association. Markers of generalized
inflammation of the acute-phase response are associated with recurrent stroke, rather than IL-6, C-reactive protein, or
fibrinogen in particular. (Stroke. 2008;39:2226-2230.)
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There is increasing evidence that inflammatory variablesare associated with atherogenesis and predict risk of
cardiovascular disease (CVD).1,2 The acute-phase reactants
C-reactive protein (CRP)3 and fibrinogen4 have been shown
to predict risk of primary ischemic stroke. One recent report
suggests that CRP may be a better risk predictor for stroke
than for coronary heart disease (CHD),5 another that the
associations are similar,6 and 1 that CRP is a moderate
predictor of ischemic stroke risk and adds no information to
the Framingham assessment.7 The association between stroke
risk and proinflammatory markers therefore requires further
investigation. It is possible that inflammatory markers “up-
stream” of the acute-phase response (APR) may explain
associations between acute-phase reactants (such as CRP and
fibrinogen) and CV events.1 Prediction of recurrent stroke is
clinically important. We have previously demonstrated that
CRP and fibrinogen predict risk of recurrent ischemic stroke
independently of conventional stroke risk markers,8 and a
meta-analysis of 3 other studies has also shown this associ-
ation with fibrinogen.9
The proinflammatory cytokines interleukin (IL)-6, IL-18,
and tumor necrosis factor- (TNF-) have all been impli-
cated as risk markers for CHD.10–19 This association may
reflect observed experimental roles in atherogenesis and
atherothrombosis for these markers,20–25 although caution
must be used in implicating causality.2 Despite recent interest
in positive associations of IL-6 gene polymorphisms with
stroke,26–29 this biomarker has been understudied as a risk
marker for ischemic stroke, and IL-18 and TNF- have only
been prospectively studied as risk markers of stroke in cohort
studies with composite end points and few stroke pa-
tients.17–19 We aimed to extend current data by examining the
association between IL-6, IL-18, and TNF- and recurrent
stroke, as well as relating these to the associations of
fibrinogen and CRP with recurrent stroke, which we have
previously reported.8
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Subjects and Methods
The design,30 principal results,31 and case-control study results8 of
the Perindopril Protection Against Recurrent Stroke Study
(PROGRESS) have been published previously. In brief, in the
principal study, 6105 patients with a history of stroke or transient
ischemic attack were recruited, and each patient was randomly
assigned active treatment (n3051) or placebo (n3054). For those
deemed suitable by the responsible physician, mono or dual therapy
was allocated: perindopril and/or indapamide, or single/double
placebo. Patients were followed up for a mean of 3.9 years, during
which time stroke occurred in 307 (10%) in the active treatment
group and in 420 (14%) in the placebo group (relative risk reduc-
tion28%; 95% CI, 17 to 38; P0.0001). At baseline, venous blood
samples collected from 5918 (97%) patients were anticoagulated
with K2EDTA and centrifuged at 2000g for 10 minutes at 4°C.
Aliquots (1.5 mL) of plasma were stored at 80°C. Owing to the
high proportion of patients from whom blood samples were taken, no
imputation of the missing samples was necessary.
The base population for the case-control study comprised all those
who had plasma frozen and stored within 48 hours of venipuncture
and whose most recent qualifying event (classified as ischemic
stroke, hemorrhagic stroke, or transient ischemic attack) at baseline
in the clinical trial occurred 1 month ago. These restrictions give
protection against deterioration of the blood samples and confound-
ing attributable to acute-phase reactant increases in blood variables
as a result of the incident stroke or its acute complications.
Stroke cases comprised anyone with a stroke recorded during
follow-up. By standard methodology for nested case-control studies
and as previously described,8 each case was randomly matched to
between 1 and 3 controls selected from all those free of recurrent
stroke at the time of recurrent stroke for that case. Matching
variables were age, sex, treatment allocation, therapy, region, and
most recent qualifying event at trial baseline, the latter variable being
the best classification available to us to describe a patient’s previous
CV history. Prespecified ischemic and hemorrhagic stroke substud-
ies isolated those cases and their matched controls who had ischemic
or hemorrhagic strokes as their first recorded stroke event.
Plasma fibrinogen and high-sensitivity CRP were both measured
by immunonephelometry as previously described.8 IL-18, high-
sensitivity IL-6, and high-sensitivity TNF- were all assayed by
ELISA (R&D Systems, Oxon, UK). Intra-assay variation was 5.6%
for IL-18, 7.5% for IL-6, and 8.4% for TNF-. Corresponding
interassay coefficients were 10.4%, 8.9%, and 12.5%, respectively.
We compared inflammatory markers and potential confounding
variables between cases and unique controls by t tests or the 2 test,
as appropriate. Odds ratios (ORs) were calculated according to equal
thirds of the distributions of each of the inflammatory markers, and
trends across these thirds were tested by using conditional logistic-
regression models.32 These were computed both with and without
adjustment for potential confounding factors (systolic blood pres-
sure, smoking, prevalence of peripheral artery disease, statin use, and
antiplatelet use) not controlled for in the matching variables. A
previous report from this study8 that used identical methods found
fibrinogen and CRP to have independent effects on ischemic stroke,
but not on hemorrhagic stroke. Thus, another model added these 2
additional inflammatory variables to the adjustment set, together
with the inflammatory variables measured for the current report, to
assess the relative independent contributions of the inflammatory
markers to risk of ischemic stroke.
Results
In this nested case-control study, there were 591 cases (472
ischemic strokes, 83 hemorrhagic strokes, and 36 of unknown
type) and 1182 controls who did not subsequently become
cases. In this substudy of PROGRESS, there were few
missing values for IL-6, IL-18, fibrinogen, or CRP (1%) but
several for TNF-, because of its being the last of the assays
performed on the limited available plasma samples. Sample
sizes for TNF- were 433 cases and 859 controls (73% of the
total).
Table 1 summarizes the baseline demographic data and
shows risk factor data according to whether the subject
became a case or not during PROGRESS. In the ischemic
stroke group, IL-6 was significantly (P0.003) higher in
cases than in controls (but not IL-18 or TNF-), as were
Table 1. Baseline Summary Data for All Subjects in the Nested Case-Control Study Classified by Whether or Not They Developed
Either of the Major Subtypes of Stroke During PROGRESS
Variable
Hemorrhagic Stroke
P Value
Ischemic Stroke
P ValueCases (n83) Controls (n199) Cases (n472) Controls (n1011)
Mean (95% CI)
Age, y* 62.5 (60.6–64.5) 62.4 (61.2–63.6) 0.92 66.5 (65.7–67.3) 66.2 (65.7–66.7) 0.48
SBP, mm Hg 149.7 (145.4–154.0) 145.9 (143.4–148.4) 0.11 149.9 (148.1–151.6) 147.4 (146.3–148.6) 0.02
Fibrinogen, g/L 3.58 (3.40–3.76) 3.76 (3.63–3.89) 0.11 3.87 (3.79–3.96) 3.73 (3.70–3.78) 0.005
CRP, mg/L† 1.47 (1.10–1.96) 1.62 (1.35–1.94) 0.57 2.20 (1.98–2.45) 1.91 (1.77–2.05) 0.03
IL-6, pg/mL† 2.00 (1.70–2.37) 2.00 (1.83–2.18) 0.99 2.44 (2.31–2.59) 2.20 (2.11–2.29) 0.003
IL-18, pg/mL† 455 (399–521) 474 (436–517) 0.59 484 (459–511) 481 (463–500) 0.84
TNF-, pg/mL† 2.61 (2.24–3.07) 2.48 (2.35–2.62) 0.54 2.56 (2.44–2.69) 2.45 (2.38–2.53) 0.15
No. (%)
Men* 63 (76) 154 (77) 0.88 348 (74) 750 (74) 0.85
Smokers 15 (18) 43 (22) 0.63 110 (23) 173 (17) 0.006
PAD 1 (1) 7 (4) 0.94 32 (7) 39 (4) 0.02
Statin use 5 (6) 13 (7) 1.00 36 (8) 77 (8) 0.99
Diabetes 6 (7) 19 (10) 0.53 85 (18) 113 (11) 0.0003
Antiplatelet use 39 (47) 104 (52) 0.42 362 (77) 780 (77) 0.85
SBP indicates systolic blood pressure; PAD, peripheral arterial disease.
*Matching variable.
†Analysed on a logarithmic scale and back-transformed to show estimates.
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several conventional risk factors for stroke (complete results
shown previously8). In the hemorrhagic stroke study, there
were no significant differences in cases and controls for the
cytokines, nor for any conventional CV risk factors.
On analysis by thirds of their distributions, none of the
cytokines showed significant associations with hemorrhagic
stroke (Table 2). The highest third of TNF- had a moder-
ately elevated risk compared with the lowest third, the
adjusted OR being 1.23, although the 95% CI was wide (0.55
to 2.75) owing to small numbers. For ischemic stroke, IL-6
showed a stepwise increase in OR across thirds, and although
the trend was reduced to borderline significance after adjust-
ment for conventional risk factors, the highest third still had
an increased risk compared with the lowest: OR1.33; 95%
CI, 1.00 to 1.78. TNF- showed somewhat similar associa-
tions, although the significance of its trend was entirely due to
the excess risk comparing the highest with the lowest third:
OR1.46; 95% CI, 1.02 to 2.10, after adjustment. For total
stroke, both IL-6 and TNF- had a more significant trend in
risk across thirds compared with the major subtypes of stroke
(owing to increased case numbers and smaller CIs). Estimates
of associations were relatively unaffected by the addition of
hemorrhagic and unknown strokes to ischemic stroke (largely
owing to the predominance of ischemic stroke). IL-18
showed no association with risk of hemorrhagic, ischemic, or
total stroke in any model.
Previously,8 we found significant independent effects of
fibrinogen and CRP: comparing the extreme thirds, the OR
for fibrinogen was 1.34 (95% CI, 1.01 to 1.78) and for CRP
it was 1.39 (95% CI, 1.05 to 1.85), after adjustment for
systolic blood pressure, smoking, prevalent peripheral artery
disease, statin use, and antiplatelet use. A summary of a
multivariable model, including classic risk markers and all 5
inflammatory markers at once, is shown in Table 3. Inclusion
of all 5 markers in the same model produced ORs for any of
the markers with ischemic stroke to near unity, with the
exception of the OR comparing the extreme thirds of TNF-,
which was 1.43 (95% CI, 0.98 to 2.10) and hence borderline
significant.
Discussion
To our knowledge, this is the first reported study of the
association between the proinflammatory cytokines IL-6,
IL-18, and TNF- and risk of recurrent stroke. We found that
IL-6 and TNF-, but not IL-18, were significant risk predic-
tors of recurrent ischemic stroke. IL-6 appeared to show
stepwise increases in risk through thirds of this population,
although the trend was less notable after adjusting for
potential confounders. For TNF-, only the top third of the
population was at statistically increased risk after adjusting
for classic risk factors. This finding is consistent with a
Table 2. ORs (95% CIs) for Hemorrhagic, Ischemic, and Total Stroke by Thirds of Each Variable
Variable/Third
Hemorrhagic Stroke Ischemic Stroke Total Stroke
Matched Adjusted* Matched Adjusted* Matched Adjusted*
IL-6, pg/mL
1 (1.70) 1 1 1 1 1 1
2 (1.70–2.94) 1.10 (0.58–2.06) 1.15 (0.60–2.21) 1.36 (1.03–1.79) 1.33 (1.01–1.77) 1.29 (1.01–1.65) 1.28 (1.00–1.64)
3 (2.94) 1.17 (0.61–2.24) 1.18 (0.61–2.27) 1.43 (1.08–1.90) 1.33 (1.00–1.78) 1.37 (1.06–1.76) 1.31 (1.01–1.69)
P for trend 0.62 0.60 0.02 0.06 0.02 0.04
IL-18, pg/mL
1 (366) 1 1 1 1 1 1
2 (366–582) 0.70 (0.37–1.33) 0.78 (0.40–1.50) 1.09 (0.83–1.44) 1.07 (0.81–1.41) 1.02 (0.79–1.30) 1.02 (0.79–1.30)
3 (582) 0.74 (0.38–1.45) 0.77 (0.39–1.53) 1.04 (0.78–1.39) 0.97 (0.72–1.29) 0.99 (0.77–1.27) 0.94 (0.72–1.21)
P for trend 0.36 0.44 0.78 0.84 0.92 0.63
TNF-, pg/mL
1 (2.17) 1 1 1 1 1 1
2 (2.17–2.89) 0.88 (0.41–1.88) 0.81 (0.37–1.80) 0.98 (0.68–1.40) 0.96 (0.67–1.39) 1.01 (0.74–1.39) 1.00 (0.73–1.38)
3 (2.89) 1.43 (0.66–3.12) 1.23 (0.55–2.75) 1.47 (1.03–2.11) 1.46 (1.02–2.10) 1.49 (1.08–2.05) 1.47 (1.07–2.03)
P for trend 0.35 0.58 0.02 0.03 0.01 0.01
*Adjusted for systolic blood pressure, smoking, prevalence of peripheral artery disease, statin use, diabetes, and antiplatelet use.
Table 3. ORs (95% CIs) for Ischemic Stroke by Thirds for Each of the 5 Variables Adjusted for the Other 4
and for Systolic Blood Pressure, Smoking, Peripheral Artery Disease Prevalence, Statin Use, Diabetes, and
Antiplatelet Use
IL-6 IL-18 TNF- Fibrinogen CRP
First third
Second third 1.11 (0.76–1.61) 0.88 (0.62–1.24) 0.93 (0.64–1.34) 1.07 (0.76–1.53) 0.95 (0.65–1.38)
Third third 0.99 (0.65–1.50) 0.92 (0.63–1.33) 1.43 (0.98–2.10) 1.02 (0.68–1.53) 1.13 (0.73–1.76)
P for trend 0.92 0.15 0.04 0.89 0.50
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previous study of recurrent myocardial infarction, which
found that only those with very high TNF- expression were
at increased risk.15
The absence of an association of any of the inflammatory
markers with hemorrhagic stroke may be due to small
numbers, although we believe it is more likely that the
observed differences are due to differing underlying pathol-
ogies of ischemic and hemorrhagic stroke. Chronic low-grade
inflammation is believed to be a key factor in atherogene-
sis,1,2,20–25 which may ultimately lead to the atherothrombotic
complications of plaque rupture such as ischemic stroke. In
contrast, hemorrhagic stroke often occurs as a result of
rupture of small intraparenchymal vessels, and such events
are often the result of hypertension or other factors not
necessarily directly causally related to atherosclerosis or
inflammation.33
A major biologic property of IL-6 and TNF- is that these
cytokines may actively participate in the hepatic stimulation
of the APR.1 There is little evidence to suggest that IL-18,
which was not associated with any major stroke subtype in
this study, directly contributes to the APR.34 As we have
previously noted in this study,8 the acute-phase reactant
behavior of fibrinogen, CRP, or any inflammatory marker
may be viewed as a potential confounder of associations with
recurrent stroke. This is because the underlying association
may be due to “generalized inflammation” (as proximally
measured by the APR) rather than the causal behavior of any
individual inflammatory marker per se.2 However, adjusting
acute-phase reactants (CRP and fibrinogen) only for each
other to remove potential APR confounding assumes that the
APR is an absolute event, with roughly equal effects on
circulating CRP and fibrinogen levels. This may not be an
accurate assumption.35
By simultaneously adjusting for CRP, fibrinogen, IL-6,
TNF-, and IL-18 (not associated with risk), we have shown
that markers of the APR (fibrinogen and CRP) and the chief
stimulator of the APR (IL-6) almost completely explain each
other’s association with recurrent stroke. This suggests that
despite evidence that IL-6, IL-18, and TNF- are involved in
experimental atherogenesis and atherothrombosis,20–25 poten-
tial associations with recurrent stroke are almost fully ex-
plained by conventional risk markers and proximity to the
APR. Equally, this suggests that CRP and fibrinogen them-
selves are associated with recurrent stroke because they are
acute-phase reactants rather than that they necessarily make
additional inflammatory contributions to atherothrombosis.
The exception to this trend is TNF-, which retained border-
line associations with risk of recurrent ischemic stroke in this
cohort after adjusting for conventional risk factors and the
APR. TNF- is a pluripotent cytokine and may be involved in
atherogenesis and atherothrombosis in mechanisms indepen-
dent of the APR, perhaps particularly in those with very high
circulating concentrations of the cytokine,15 eg, in those with
rheumatoid arthritis.36 Despite this, the risk association in the
current cohort by thirds of the population is modest and
unlikely to provide appreciable clinical utility, although this
requires verification in larger cohorts. The lack of association
of IL-18 with risk of recurrent stroke is in contrast to some
studies that prospectively showed that IL-18 was associated
with risk of CHD events.13,14 However, this finding has not
been universal in cohorts after full adjustment for potential
confounders in multivariable models.37 Thus, IL-18 may be
related to CHD as a heavily confounded variable, such as by
associations with lipid parameters, which are not strongly
related to ischemic stroke.38 Residual associations of IL-18
with CHD risk may be due to specific roles in inflammatory
pathways (eg, interferon-– dependent atherogenesis39),
which have yet to be directly related to risk of recurrent
ischemic stroke.
Just as caution must be used in drawing conclusions of
causality in epidemiologic studies,2 it is equally important not
to exclude causality on the same basis. It is quite possible
(perhaps probable) that some inflammatory markers actively
participate in atherogenesis and atherothrombosis, at least
partially through other conventional risk factors (eg, the
association of inflammation with smoking or cholesterol
levels). However, associations of inflammatory markers of
the APR (IL-6, CRP, and fibrinogen) with recurrent stroke
were fully explained by conventional risk markers and APR
confounding in this model. This suggests that from the
inflammatory markers measured in this study, it is only
“general inflammation” rather than a particular marker that is
strongly associated with secondary ischemic stroke. More
studies are required to expand on these findings, both for
primary and secondary stroke as well as CHD.
Summary
Inflammatory markers associated with the APR (IL-6,
TNF-, CRP, and fibrinogen, but not IL-18) are associated
with risk of recurrent stroke. These markers are dependent on
each other in multivariable models, and once all were
included, only TNF- retained a borderline association. This
suggests that markers of generalized inflammation of the
APR are associated with recurrent stroke, rather than IL-6,
CRP, or fibrinogen in particular.
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